Expiration date: 10/2025

Action:

A selective, competitive inhibitor of HMG-COA reductase

Composition:

Rosuvastatin, excipients

Indications:

Primary hypercholesterolemia according to the classification of Fredrickson (type IIa, including family heterozygous hypercholesterolemia) hypercholesterolemia or mixed (type IIb) as an adjunct to diet when diet and other non-pharmacological treatments (e.g. exercise, weight reduction) are inadequate. Family homozygous hypercholesterolemia as an adjunct to diet and other Lipetskaya therapy (eg, LDL-apheresis), or in cases where such therapy is not effective enough. Hypertriglyceridemia (type IV according to the classification of Frederickson) as a Supplement to the diet. For slowing the progression of atherosclerosis as an adjunct to diet in patients who have shown therapy to reduce the concentration of total cholesterol and cholesterol-LDL. Primary prevention of major cardiovascular complications (stroke, infarction, arterial revascularization) in adults without clinical signs of coronary heart disease (CHD), but with an increased risk of its development